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Abstract
Transient receptor potential canonical-6 (TRPC6) ion channels, expressed at high levels in podocytes of the filtration barrier, are recently impli-
cated in the pathogenesis of various forms of proteinuric kidney diseases. Indeed, inherited or acquired up-regulation of TRPC6 activities are
suggested to play a role in podocytopathies. Yet, we possess limited information about the regulation of TRPC6 in human podocytes. Therefore,
in this study, we aimed at defining how the protein kinase C (PKC) system, one of the key intracellular signalling pathways, regulates TRPC6
function and expression. On human differentiated podocytes, we identified the molecular expressions of both TRPC6 and several PKC isoforms.
We also showed that TRPC6 channels are functional since the TRPC6 activator 1-oleoyl-2-acetyl-sn-glycerol (OAG) induced Ca2+-influx to the
cells. By assessing the regulatory roles of the PKCs, we found that inhibitors of the endogenous activities of classical and novel PKC isoforms
markedly augmented TRPC6 activities. In contrast, activation of the PKC system by phorbol 12-myristate 13-acetate (PMA) exerted inhibitory
actions on TRPC6 and suppressed its expression. Importantly, PMA treatment markedly down-regulated the expression levels of PKCa, PKCb,
and PKCg reflecting their activation. Taken together, these results indicate that the PKC system exhibits a ‘tonic’ inhibition on TRPC6 activity in
human podocytes suggesting that pathological conditions altering the expression and/or activation patterns of podocyte-expressed PKCs may
influence TRPC6 activity and hence podocyte functions. Therefore, it is proposed that targeted manipulation of certain PKC isoforms might be
beneficial in certain proteinuric kidney diseases with altered TRPC6 functions.
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Introduction
Transient receptor potential cation channel 6 (TRPC6) is a member of
the large TRP channel superfamily. The human TRPC6 is a non-selec-
tive cation channel that is directly activated by diacylglycerol (DAG) in
a membrane-delimited fashion [1–3]. Based on the described activa-
tion characteristics, TRPC6 represents a new member of the second-
messenger-operated cation channels, which are activated by DAG [1].
It has been shown that tyrosine phosphorylation of TRPC6 induces a
complex formation with phospholipase (PLC-c1), which is prerequi-
site for TRPC6 surface expression. Activation of TRPC6 by DAG ana-
logues, such as 1-oleoyl-2-acetyl-sn-glycerol (OAG), results in
elevated intracellular Ca2+-level which then triggers multiple down-
stream signalling events.
Immunofluorescence staining revealed TRPC6 expression
throughout the kidney in the glomeruli and tubules [4–6]. Although all
cell types within the glomeruli express TRPC6 [7], the highest level of
expression of TRPC6 was detected in the glomerular epithelial
cells, also known as podocytes. In these cells, TRPC6 was shown
to be functionally connected to the actin cytoskeleton [8–10].
Abnormal podocyte function appears to be the final common
pathway in a variety of proteinuric kidney diseases [5, 9, 11–14].
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Focal segmental glomerulosclerosis (FSGS) is a pathologic entity that
is a common cause of nephrotic syndrome in both adults and
children. The clinical hallmarks of FSGS include proteinuria, nephrotic
syndrome and frequently progressive loss of renal function. Several
causative genes encoding mostly regulatory- and structural
proteins (nephrin, podocin, WT-1 and a-actinin-4) have been identi-
fied in the pathogenesis of FSGS with a typical clinical course of thera-
peutic resistant nephrotic syndrome and associating severe proteinuria
[15–18].
Intriguingly, both genetic and acquired malfunctions of TRPC6
channels were implicated in proteinuric kidney diseases [9, 14, 19,
20]. For example, mutation of the trpc6 gene causes a particularly
aggressive form of FSGS [4, 5, 21]. The ‘gain-of-function’ P112Q
mutation in TRPC6 causes enhanced Ca2+ entry and a particularly
exaggerated response to G-protein agonists such as angiotensin II
[5]. Based on in vitro and in vivo data, it has been suggested that the
abnormal TRPC6 function may cause an increase in intracellular Ca2+-
level and affects critical interactions with podocyte structural pro-
teins, leading to abnormalities in the slit diaphragm and/or podocyte
foot processes [4, 5, 22].
The protein kinase C (PKC) isoenzyme family establishes one of
the central regulatory signal transduction pathways involved in practi-
cally all major cellular functions. Apparently, the PKC system is also
involved in the regulation of kidney functions. For example, PKCa was
shown to have a key role in the signalling response after stimulation
with transforming growth factor-b (TGFb), a protein which promotes
podocyte death and development of glomerulosclerosis [23]. Others
reported the up-regulation of PKCb2 isoform in human proliferative
glomerulonephritis [24]. Likewise, up-regulation of PKCa and b was
observed in experimental model of membranous glomerulonephritis
[25].
Although (i) the PKC activator phorbol 12-myristate 13-acetate
(PMA) was reported to induce a decrease in TRPC6 expression in kid-
ney mesangial cells which was reversed by the inhibition of nuclear
factor kB (NF-jB) suggesting the involvement of PKCs in this sig-
nalling event [26]; and (ii) in various heterologous systems, PKCs
were shown to modulate various TRPs, including TRPC6 [27, 28], we
lack evidence on the potential of PKC-dependent regulation of na€ıve
TRPC6 functions in podocytes, especially of human origin. Therefore,
in this study, we aimed at investigating the expression and PKC-de-
pendent functional modulation of TRPC6 channels on human cultured
podocytes. In this article, we provide the first evidence that certain
PKC isoforms exert a ‘tonic’ inhibitory effect on TRPC6 function sug-
gesting that pathological conditions altering the expression and/or
activation patterns of podocyte-expressed PKCs may influence TRPC6
activity, expression and hence podocyte functions.
Materials and methods
Chemicals
The OAG, the PMA, and GF109203X were obtained from Sigma-Aldrich
(St Louis, MO, USA) whereas G€o6983 and Rottlerin were purchased
from Calbiochem (Nottingham, UK).
Antibodies
The following antibodies were employed in this study: rabbit anti-human
TRPC6 (Alomone Labs, Jerusalem, Israel); rabbit anti-human podocin
(Abcam, Cambridge, UK) for immunocytochemistry and another one
from Santa Cruz (Heidelberg, Germany) for Western blotting; mouse
anti-human synaptopodin (Progen, Heidelberg, Germany); rabbit anti-hu-
man PKCa, rabbit anti-human PKCd and rabbit anti-human PKCf
(Biomol Res Lab, Plymouth Meeting, PA, USA); rabbit anti-human
PKCk/ι (Santa Cruz); rabbit anti-human PKCb1, rabbit anti-human
PKCb2, rabbit anti-human PKCc, rabbit anti-human PKCe, rabbit anti-hu-
man PKCg, rabbit anti-human PKCh and rabbit anti-human b-actin
(Sigma-Aldrich).
Cell culturing
The human podocyte cell line was established and cultured as described
previously [29]. In brief, cells were cultured in RPMI-1640 medium
(PAA Laboratories GmbH, Pasching, Austria) supplemented with 10%
foetal bovine serum (Invitrogen, Paisley, UK), 50 U/ml penicillin, 50 lg/
ml streptomycin, 1.25 lg/ml Fungizone (both from PAA Laboratories
GmbH) and insulin-transferrin-selenium (1:100; Invitrogen) at 33°C
(‘permissive’ conditions). Differentiation was induced by transferring
cells to 37°C and kept in culture for 7 days (‘non-permissive’ condi-
tions). The process of differentiation was assessed using Western blot-
ting and immmunocytochemistry (Figure 1 and Supplementary Figure
S1) by determining the expression of the podocyte-specific marker
podocin and the differentiation marker synaptopodin.
Immunocytochemistry
Human differentiated podocytes were cultured on glass coverslips in
6-well plates, were fixed by acetone for 5 min. at room temperature,
and permeabilized by 0.6% Triton-X-100 (Sigma-Aldrich) in PBS
(115 mM NaCl, 20 mM Na2PO4, pH 7.4; all from Sigma-Aldrich) for
10 min. Following 30 min. incubation in blocking solution [0.6% Triton-
X-100 and 1% bovine serum albumin (BSA) containing PBS; Sigma-
Aldrich] at room temperature, cells were probed with the previously
mentioned primary antibodies raised against TRPC6 (1:50), podocin
(1:100) and synaptopodin (1:100) overnight at 4°C. Following appropri-
ate washing in PBS, coverslips were incubated with Alexa-488-conju-
gated goat anti-mouse and goat anti-rabbit secondary antibodies (1:200,
Invitrogen) for 1 hr at room temperature. Nuclei were counterstained
with propidium-iodide (Vector Laboratories, Peterborough, UK). Nega-
tive control cells were stained omitting the primary antibodies. Visual-
ization of the proteins was performed using Zeiss LSM 510 Meta
Confocal Microscope (Zeiss, Oberkochen, Germany). The exposure time
and all other settings (gain, gamma and intensity of the excitation) were
exactly the same in all cases, including the negative controls.
Western blot
Cells were harvested and homogenized in protease inhibitor cocktail
(1:100; Sigma-Aldrich) containing detergent mixture (50 mM TRIS HCl,
150 mM NaCl, 1% Triton X-100, 1% Igepal CA 630, 0.5% sodium
deoxicholate; Sigma-Aldrich). Protein concentrations were determined
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by BCA reagent (Pierce, Rockford, IL, USA) and set to 1 lg/ml. Equal
protein samples (6 lg/well) were subjected to SDS-PAGE (10% Mini
Protean TGX gels; Bio-Rad, Hercules, CA, USA), and transferred to
nitrocellulose membranes, by Trans-Blot TurboTM Nitrocellulose Trans-
fer Packs and Trans Blot Turbo System (both from Bio-Rad). Mem-
branes were probed with the corresponding primary antibodies
mentioned above (anti-TRPC6 1:500; anti-podocin, 1:100; anti-synap-
topodin 1:100; anti-PKCa 1:100; anti-PKCb1 1:100; anti-PKCb2 1:100;
anti-PKCc 1:100; anti-PKCd 1:100; anti-PKCe 1:100; anti-PKCf 1:100
anti-PKCg 1:100; anti-PKCh 1:100; anti-PKCk/ι 1:50) in 5% milk con-
taining PBS overnight at 4°C. As secondary antibodies, horseradish per-
oxidase-conjugated goat anti-mouse and goat anti-rabbit IgGs (1:1000;
Bio-Rad) were employed and the immunoreactive bands were visualized
by a SuperSignal West Pico Chemiluminescent Substrate-Enhanced
Chemiluminescence kit (Pierce) using LAS-3000 Intelligent Dark
Box (Fuji, Tokyo, Japan) Gel Logic 1500 Imaging System (Kodak,
Tokyo, Japan). To assess equal loading, membranes were re-probed
using a rabbit anti-b-actin antibody (1:1000; Sigma-Aldrich). Densito-
metric analysis was performed using KODAK Molecular Imaging Sys-
tems (Eastman Kodak Company, Rochester, NY, USA).
RT-PCR
Total RNA was isolated using TRIzol (Invitrogen) as described by Toth
et al. 2011 [30], and the isolated total RNA was reverse-transcribed into
cDNA and then amplified on a GeneAmp PCR System 2400 DNA Ther-
mal Cycler (Applied Biosystems, Foster City, CA, USA). Primers were
synthesized by Integrated DNA Technologies (Leuven, Belgium) (TRPC6,
forward: 50-TCAATCTGGTGCCGAGTCCAAAGT-30, reverse: 50-TTTATGGCC
CTGGAACAGCTCAGA-30, 86 bp; glyceraldehyde-3-phosphate dehydroge-
nase, forward: 50-AATGAGCCCCAGCCTTCTCCAT-30, reverse: 50-AAGGTC
GGAGTCAACGGATTTGG-30, 322 bp). PCR products were visualized on
1.5% agarose gel with EZ-Vision DNA Dye (Amresco, Solon, OH, USA)
under UV.
Fluorescent Ca2+-imaging
Fluorescent Ca2+-imaging was performed by applying two complemen-
tary approaches. In multi-well format imaging, according to our previ-
ously optimized protocol [31, 32], human podocytes were seeded in
96-well/clear-bottom plates (Greiner Bio-One, Kremsmuenster, Austria)
at a density of 20,000 cells per well in podocyte medium and cultured
at ‘non-permissive’ conditions for 7 days. On day 7, the cells were
washed once with 1% BSA (Sigma-Aldrich) and 2.5 mM Probenecid
(Sigma-Aldrich) containing Hank’s solution (136.8 mM NaCl, 5.4 mM
KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 0.81 mM MgSO4,
1.26 mM CaCl2, 5.56 mM glucose, 4.17 mM NaHCO3, pH 7.2, all from
Sigma-Aldrich) than loaded with 1 lM Fluo-4 AM (Life Technologies
Corporation, Carlsbad, CA, USA) containing Hank’s solution (100 ll/
well) at 37°C for 30 min. The cells were washed three times with
Hank’s solution (100 ll/well; in the case of the ‘low Ca2+ Hank’ the
CaCl2 content was supplemented by equimolar glucose). The plates
were then placed into a FlexStation II384 Fluorescence Imaging Plate
Reader (Molecular Devices, Sunnyvale, CA, USA) and changes in
[Ca2+]i (reflected by changes in fluorescence; kEX = 494 nm,
kEM = 516 nm) induced by various concentrations of the drugs were
recorded in each well (during the measurement, cells in a given well
were exposed to only one given concentration of the agent). Experi-
ments were performed in triplicates and the averaged data (as well as




Fig. 1 Assessment of in vitro differentia-
tion of human podocytes. Expression of
differentiation/podocyte markers podocin
and synaptopodin as determined by Wes-
tern blot analysis (A) on human podo-
cytes. To assess equal loading, expression
of b-actin was determined. Pre: pre-con-
fluent (proliferating) culture; Post: post-
confluent (proliferating) culture; Diff: dif-
ferentiated culture. Podocin (B) and
synaptopodin (C) immunoreactivity was
determined on differentiated human podo-
cytes by immunofluorescence labelling
(Alexa-Fluor-488, green fluorescence).
Nuclei were counterstained by propidium
iodide (red fluorescence). Calibration
mark: 50 lm. NC: negative control.
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
3
J. Cell. Mol. Med. Vol XX, No X, 2015
For single-cell imaging [32], changes in [Ca2+]i were measured using
the calcium sensitive fluorescent dye Fura-2 (Invitrogen) as reported
previously [33]. In brief, podocytes were seeded to coverslips and incu-
bated with Fura-2 AM (10 lM) for 1 hr (37°C) in RPMI supplemented
with neostigmin to inhibit acethylcholinesterase. Furthermore, cells were
equilibrated in normal Tyrode’s solution [NTY; 137 mM NaCl, 5.4 mM
KCl, 0.5 mM MgCl2, 1.8 mM CaCl2, 11.8 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1 g/l glucose, pH 7.4, all from
Sigma-Aldrich] for 30 min. at room temperature. Coverslips with the
Fura-2 loaded cells were then placed on the stage of an inverted fluo-
rescent microscope (Diaphot; Nikon, Tokyo, Japan). Measurements
were performed in NTY. Cells were continuously washed with NTY per-
formed with a background perfusion system. Test solutions were
directly applied onto the cells through a perfusion capillary tube (Perfu-
sion PencilTM; AutoMate Scientific, Inc., San Francisco, CA, USA) with an
internal diameter of 250 lm at a 0.35 ml/min. rate, performed with a
local perfusion system (Valve BankTM 8 version 2.0; AutoMate Scientific,
Inc., Berkeley, CA, USA). All measurements were performed at room
temperature. Excitation wavelength was alternated between 340 and
380 nm by a dual wavelength monochromator (Deltascan; Photon Tech-
nology International, New Brunswick, NJ, USA), while the emission was
monitored at 510 nm performed with a photomultiplier.
Statistical analysis
When applicable, data were analysed using a two-tailed unpaired t-test
and P < 0.05 values were regarded as significant differences.
Further information about the applied methods can be found in the
Supplementary Materials an Methods section.
Results
TRPC6 channels are functionally expressed on
human podocytes
First, we intended to characterize the expression of TRPC6 on cul-
tured, differentiated human podocytes. As revealed by RT-PCR as well
as by Western blotting and immunocytochemistry, TRPC6 channels
are expressed by human differentiated podocytes, both at the mRNA
and protein levels (Figure 2A–C). Specificity of the TRPC6 antibody





Fig. 2 Transient receptor potential canonical-6 (TRPC6) is expressed and functionally active in human podocytes. (A) RT-PCR analysis of TRPC6
transcripts in non-differentiated (Non-Diff) and differentiated (Diff) human podocytes. As an internal control, transcripts of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was determined. No-RT: ‘no-RT/water only’ control. (B) Western blot analysis of lysates of human non-differentiated
and differentiated podocytes. To assess equal loading, expression of b-actin was determined. (C) Immunocytochemistry. TRPC6-specific immunore-
activity was determined by immunofluorescence labelling (Alexa-Fluor-488, green fluorescence) in human differentiated podocytes. Nuclei were
counterstained by Propidium iodide (red fluorescence). Calibration mark: 50 lm. NC: negative control. (D) Representative multi-well fluorescent
Ca2+-imaging measurement. Compound was applied as indicated by the bar. OAG: 1-oleoyl-acetyl-sn-glycerol. (E) Statistical analysis of Ca2+-imaging
data (n = 3 experiments in each case). *** mark significant (P < 0.001).
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cells (Supplementary Materials and methods; Supplementary Figure
S2). We then assessed the functional presence of these channels by
employing Fluo 4-AM-based Ca2+-imaging. As shown in Figure 2D
and E, the TRPC6 activator OAG markedly increased intracellular
Ca2+-level of the cells. Importantly, this effect was almost completely
abolished by the removal of the extracellular Ca2+ suggesting that the
OAG induced Ca2+-influx to the cells, most probably via TRPC6.
Human podocytes express multiple PKC
isoenzymes
Since the major goal of this study was to uncover the potential role of
the PKC system in the regulation of TRPC6, we then determined the
PKC isoform pattern of human differentiated podocytes (which has
not been extensively investigated so far). As revealed by Q-PCR (Sup-
plementary Materials and methods; Supplementary Figure S3) and
Western blotting (Figure 3), human podocytes express multiple PKC
isoenzymes; namely, the presence of the conventional cPKCa, b1, b2
and c; the novel nPKCd, e, g and h; and the atypical aPKCf were
indentified (the expression of aPKCk/ι was not detected, data not
shown).
Suppression of endogenous PKC activities
markedly affects OAG-induced TRPC6 activation
We then assessed whether the modulation of the endogenous activi-
ties of these PKC isoforms (especially of those which showed high
levels) affect the function of TRPC6. For this, human podocytes were
pretreated for 30 min. with GF109203X (inhibitor of the conventional
and novel PKCs); G€o6976 (inhibitor of the classical isoforms); and
Rottlerin (inhibitor of PKCd) and then cells were challenged by the
TRPC6 activator OAG. As seen in Figure 4, all inhibitors markedly and
statistically significantly augmented the effect of OAG to induce
TRPC6-mediated Ca2+-elevation in the cells. These data suggest that,
in differentiated human podocytes, the endogenous activities of clas-
sical and novel PKCs exert a constitutively present, ‘tonic’ inhibition
on TRPC6.
We then intended to investigate whether the activation of the PKC
system (in other words, the exogenous augmentation of activities of
the expressed PKC isoforms) also affect TRPC6 function. For this, fol-
lowing the above protocol, podocytes were pre-incubated with the
‘general’ PKC activator PMA (which activates both conventional and
novel PKCs) for 30 min. and then OAG was administered. As
expected, in perfect line with data obtained with the PKC inhibitors,
PKC activation by PMA treatment significantly abrogated the TRPC6-
mediated Ca2+-signal induced by OAG (Figure 5), which findings fur-
ther argue for the inhibitory effects of certain PKC isoforms on TRPC6
function.
It is generally accepted that the down-regulation of PKC isoforms
indicates their activation [34, 35]. Therefore, to further assess the
above proposal, we next investigated whether PMA treatment affects
expressions of certain, PMA-sensitive isoforms. Indeed, PMA
markedly down-regulated the levels of both the conventional PKCa
and PKCb1 in a time-dependent fashion (Figure 3). Interestingly, a
marked suppression of expression of PKCb2 was also observed after
Fig. 3Multiple protein kinase C (PKC) isoforms are expressed and mod-
ulated by phorbol 12-myristate 13-acetate (PMA) in human podocytes.
Human differentiated podocytes were treated with 100 nM PMA for the
times indicated (control represents the 0 time-point) and then Western
blot analyses were performed to assess expression levels of the PKC
isoenzymes. Immunoreactive bands were then subjected to densitomet-
ric analyses and the optical density (OD) values were determined. Num-
bers indicate OD values compared to those of the control expressions
(regarded as 1). For loading control, the expression of b-actin was
determined. These images are representatives from multiple experi-
ments (n = 3 experiments in each case except for PKCa, PKCd and
PKCe, where n = 6, 4 and 4, respectively).
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30 min.; however, longer treatment with PMA did not decrease the
level of this isoform. In addition, PMA-induced down-regulation was
also observed in the case of the Ca2+-insensitive novel PKCg. Levels
of the other PMA-sensitive isoforms, as well as of the PMA-insensi-
tive PKCf, were not suppressed by the phorbol-ester treatment.
Previous studies on cultured glomerular mesangial cells sug-
gested that PMA treatment suppresses the expression of TRPC6 [26,
36]. Therefore, we also assessed whether the PMA-induced ‘func-
tional’ inhibition of TRPC6 is also accompanied by modulating its
expression, when performed with Western blotting. Importantly, as
shown in Figure 5E, PMA treatment markedly suppressed TRPC6
expression in a similar time-dependent fashion seen in the cases of
PKC isoform down-regulation.
Discussion
In current study, we investigated the expression and functional modu-
lation of TRPC6 channels by the PKC system on human cultured
podocytes. Here, we provide the first evidence that, among the vari-
ous PKC isoenzymes expressed by these cells, certain PKC isoforms
(PKCa, b1, g and possibly b2) exert a constitutive ‘tonic’ inhibition on
TRPC6 functions expressed by human podocytes. This argument was
supported by the following complementary molecular and pharmaco-
logical data: (i) Inhibition of the endogenous PKC activities by
GF109203X (inhibitor of the cPKCs and nPKCs), G€o6986 (inhibitor of
the cPKCs) or Rottlerin (inhibitor of PKCd) all significantly augmented




Fig. 4 Protein kinase C (PKC) inhibitors augment the transient receptor potential canonical-6 (TRPC6)-mediated Ca2+-response in human podocytes.
Single-cell Ca2+-measurements. OAG (200 lM) was applied as indicated by the bars. (A) Control conditions (no pretreatment). (B–D) Effects of pre-
treatment with the general PKC blocker GF109203X (1 lM, B), G€o6976, inhibitor of cPKC isoforms (1 lM, C), or Rottlerin, inhibitor of PKCd (1 lM,
D) on the OAG-induced Ca2+-response. (E and F) Statistical analyses of the above Ca2+-imaging data. Measured peak amplitudes (E) and maximal
rate of rise of the transients (F) were plotted as mean  SEM of multiple independent determinations as indicated above the corresponding col-
umns. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the control group.
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Conversely, activation of the cPKC and nPKCs by PMA significantly
suppressed the TRPC6-mediated Ca2+-elevation (Figure 5); (iii) Treat-
ment of human podocytes by PMA down-regulated the expression of
certain PKCs (i.e. of PKCa, b1, b2, and g), reflecting their activation
(Figure 3); and (iv) Activation of the PKC system (presumably of the
above isoforms) by PMA also resulted in the suppression of TRPC6
expression by podocytes (Figure 5).
As detailed in the Introduction section, both TRPC6 and the PKC
systems have been implicated in numerous physiological and patho-
physiological regulatory processes of the kidney and its podocytes.
However, the relationship between the two key signalling systems
was previously described only on cultured kidney mesangial cells
where the application of PMA was shown to suppress TRPC6 levels
[26]. Since, in our present study, the effect of PKC activation on
down-regulating TRPC6 expression was described on human
podocytes as well, it is tempting to propose that the PKC system
exerts an overall inhibitory effect on kidney TRPC6 signalling.
The major message of our paper is that the above inhibitory
action of the PKC system on TRPC6 expressed by human podo-
cytes is not only realized at the molecular expression level but also
on the functional level. Moreover, we have also identified certain
PKC isoforms that are most likely involved in mediating the ‘tonic’,
PKC-mediated inhibition of TRPC6 function. Interestingly, very simi-
lar phenomena were identified on other cell types. On noradrener-
gic neurons, TRPC6 channel activity, which was markedly
augmented by OAG, was significantly inhibited by PKC activation
[37]. Likewise, Bousquet et al. [27] have shown that application of
PMA inhibited whereas of GF109203X augmented agonist-induced,
TRPC6-coupled Ca2+-entry on smooth muscle cells which inhibitory
action was suggested to be mediated by the selective involvement
of PKCd. In our hands, on human podocytes, administration of
Rottlerin, an inhibitor of PKCd, significantly augmented the OAG-in-
duce Ca2+-response (Figure 4); however, PMA treatment did not
modify the expression of this isoform (Figure 5). Since Rottlerin
was shown to modulate activities of numerous other kinase sys-
tems [38, 39], here we cannot exclude the possibility that the effect
of Rottlerin to increase TRPC6-mediated Ca2+-signal is due to its






Fig. 5 Phorbol 12-myristate 13-acetate (PMA) suppresses transient receptor potential canonical-6 (TRPC6) activity and expression in human podocytes.
(A and B) Single-cell Ca2+-measurements. OAG (200 lM) was applied as indicated by the bars. (A) Control conditions (no pretreatment). (B) Effects of
1 lM PMA-pretreatment (30 min.) on the OAG induced Ca2+-responses. (C and D) Statistical analysis of the Ca2+-measurement data. Measured peak
amplitudes (C) and maximal rate of rise of the transients (D) were plotted as mean  SEM of multiple independent determinations as indicated above the
corresponding columns. *P < 0.05 compared to the control group. (E) Assessment of TRPC6 expression by Western blotting after 100 nM PMA treat-
ment. Immunoreactive bands were subjected to densitometric analyses and the optical density (OD) values were determined. Numbers indicate OD values
compared to those of the control expressions (regarded as 1). For loading control, the expression of b-actin was determined (n = 3 experiments).
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Our findings might have clinical implications. As detailed above,
molecular and/or functional overexpression and/or malfunction of
TRPC6 has been observed in a wide variety of genetic and acquired
kidney disorders associated with different degrees of proteinuria [4,
5, 9]. In these conditions, a pathologically altered, TRPC6-controlled
intracellular Ca2+ homeostasis was suggested to play a key role in the
development of podocytopathies. Interestingly, in several of these
diseases, altered PKC isoform expression patterns were also
described. For example, up-regulation of PKCb isoform was found in
human proliferative glomerulonephritis [24] and of PKCa and b in
membranous glomerulonephritis [25]. In these studies, however, it
was not clearly shown that the elevated PKC levels were also accom-
panied by increased PKC activities. Likewise, the causative, functional
relationship between the pathological expression patterns and levels
of TRPC6 and of PKCs is also not obvious.
In this context, our findings that activities of certain PKC iso-
forms (PKCa, b1, b2, g) in human cultured podocytes significantly
modulate TRPC6 expression and function are of great importance.
Along these lines, it is proposed that pathological in vivo conditions
altering the expression and/or activation patterns of podocyte-ex-
pressed PKCs may influence TRPC6 activity and hence podocyte
functions. Therefore, further pre-clinical and clinical studies are
now invited to uncover whether the targeted manipulation of activi-
ties of certain PKC isoforms might be beneficial in the therapeutic
management of given proteinuric kidney diseases with altered
TRPC6 functions.
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